DE69630325D1 - Nervenschutzende für Auge von Säugern unter Anwendung von Kaliumkanalblockern - Google Patents

Nervenschutzende für Auge von Säugern unter Anwendung von Kaliumkanalblockern

Info

Publication number: DE69630325D1
Authority: DE; Germany
Prior art keywords: potassium channel; channel blockers; nerve endings; mammalian eyes; pharmaceutical composition
Prior art date: 1995-04-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69630325T

Other languages

English (en)

Other versions

DE69630325T3 (de

DE69630325T2 (de

Inventor

Joseph S Adorante

Elizabeth Woldemussie

Guadalupe Ruiz

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Allergan Inc

Original Assignee

Allergan Sales LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-28

Filing date

1996-04-16

Publication date

2003-11-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23710776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69630325(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-04-16 Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC

2003-11-13 Publication of DE69630325D1 publication Critical patent/DE69630325D1/de

2004-07-29 Application granted granted Critical

2004-07-29 Publication of DE69630325T2 publication Critical patent/DE69630325T2/de

2009-11-19 Publication of DE69630325T3 publication Critical patent/DE69630325T3/de

2016-04-17 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000003450 potassium channel blocker Substances 0.000 title abstract 2
210000001640 nerve ending Anatomy 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 abstract 3
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 abstract 2
108010023798 Charybdotoxin Proteins 0.000 abstract 1
235000001258 Cinchona calisaya Nutrition 0.000 abstract 1
208000010412 Glaucoma Diseases 0.000 abstract 1
241000238631 Hexapoda Species 0.000 abstract 1
206010030043 Ocular hypertension Diseases 0.000 abstract 1
HSFKQYJRJBEWKH-XTHGXZEWSA-N Paspalicine Chemical compound C1=CC=C2C(C[C@@H]3CC[C@@H]4[C@]([C@@]53C)(C)CC[C@]36OC([C@H](C(=O)C=C34)O6)(C)C)=C5NC2=C1 HSFKQYJRJBEWKH-XTHGXZEWSA-N 0.000 abstract 1
HSFKQYJRJBEWKH-UHFFFAOYSA-N Paspalicine Natural products C1=CC=C2C(CC3CCC4C(C53C)(C)CCC36OC(C(C(=O)C=C34)O6)(C)C)=C5NC2=C1 HSFKQYJRJBEWKH-UHFFFAOYSA-N 0.000 abstract 1
JDUWHZOLEDOQSR-JKPSMKLGSA-N Penitrem A Chemical compound O([C@H]1[C@H]2[C@@](C(N3)=C11)(C)[C@@]4(C)CC[C@@H]5O[C@@H]([C@@H]([C@H]6O[C@@]56[C@]4(O)CC2)O)C(=C)C)C(C)(C)[C@H]2C[C@H]4[C@]2(O)C2=C1C3=CC(Cl)=C2CC4=C JDUWHZOLEDOQSR-JKPSMKLGSA-N 0.000 abstract 1
102000004257 Potassium Channel Human genes 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
CNVQLPPZGABUCM-LIGYZCPXSA-N ctx toxin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@@H](C(N[C@@H](CC=4C5=CC=CC=C5NC=4)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3NC=NC=3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N2)C(C)C)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC1=O)=O)CCSC)C(C)C)[C@@H](C)O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 CNVQLPPZGABUCM-LIGYZCPXSA-N 0.000 abstract 1
VDNVVLOBNHIMQA-UHFFFAOYSA-N iberiotoxin Chemical compound C1SSCC(C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(O)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C1NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(C(C)C)NC(=O)CNC(=O)C(CC=1C=CC=CC=1)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CCCCN)NC1=O)CSSCC1NC(=O)C(C(C)C)NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)NC1=O)CSSCC1NC(=O)C(CC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(O)=O)NC(=O)C(C(C)O)NC(=O)C(NC(=O)C1NC(=O)CC1)CC1=CC=CC=C1 VDNVVLOBNHIMQA-UHFFFAOYSA-N 0.000 abstract 1
108010068927 iberiotoxin Proteins 0.000 abstract 1
229930005303 indole alkaloid Natural products 0.000 abstract 1
150000002475 indoles Chemical class 0.000 abstract 1
JDUWHZOLEDOQSR-UHFFFAOYSA-N penitrem A Natural products C1CC2(O)C34OC4C(O)C(C(=C)C)OC3CCC2(C)C(C(N2)=C34)(C)C1C3OC(C)(C)C1CC3C1(O)C1=C4C2=CC(Cl)=C1CC3=C JDUWHZOLEDOQSR-UHFFFAOYSA-N 0.000 abstract 1
108020001213 potassium channel Proteins 0.000 abstract 1
229960000948 quinine Drugs 0.000 abstract 1
239000003053 toxin Substances 0.000 abstract 1
231100000765 toxin Toxicity 0.000 abstract 1
108700012359 toxins Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Ophthalmology & Optometry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Eye Examination Apparatus (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DE69630325T 1995-04-28 1996-04-16 Nervenschutzende für Auge von Säugern unter Anwendung von Kaliumkanalblockern Expired - Lifetime DE69630325T3 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/431,170 US5573758A (en)	1995-04-28	1995-04-28	Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US431170		1995-04-28

Publications (3)

Publication Number	Publication Date
DE69630325D1 true DE69630325D1 (de)	2003-11-13
DE69630325T2 DE69630325T2 (de)	2004-07-29
DE69630325T3 DE69630325T3 (de)	2009-11-19

Family

ID=23710776

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE69630325T Expired - Lifetime DE69630325T3 (de)	1995-04-28	1996-04-16	Nervenschutzende für Auge von Säugern unter Anwendung von Kaliumkanalblockern
DE69624234T Expired - Lifetime DE69624234D1 (de)	1995-04-28	1996-04-16	Verfahren zur senkung des intrakulären druckes im auge von säugern unter anwendung von kaliumkanalblokker

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE69624234T Expired - Lifetime DE69624234D1 (de)	1995-04-28	1996-04-16	Verfahren zur senkung des intrakulären druckes im auge von säugern unter anwendung von kaliumkanalblokker

Country Status (8)

Country	Link
US (1)	US5573758A (de)
EP (2)	EP1243270B2 (de)
JP (2)	JPH11504330A (de)
AT (2)	ATE225658T1 (de)
AU (1)	AU703241B2 (de)
DE (2)	DE69630325T3 (de)
ES (2)	ES2204879T5 (de)
WO (1)	WO1996033719A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0868186B1 (de)	1995-12-21	2005-03-02	Alcon Laboratories, Inc.	Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
US5925342A (en) *	1996-11-13	1999-07-20	Allergan	Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US6548535B2 (en)	2000-01-18	2003-04-15	Merck & Co., Inc.	Method for treating ocular hypertension
JP2003520245A (ja) *	2000-01-18	2003-07-02	メルクエンドカムパニーインコーポレーテッド	高眼圧症を治療するための眼科組成物
ATE388400T1 (de) *	2001-01-30	2008-03-15	Merck & Co Inc	Verfahren zur identifizierung von maxi-k-kanal- blockern
JP2004520379A (ja) *	2001-01-30	2004-07-08	メルク　エンド　カムパニー　インコーポレーテッド	高眼圧治療用眼薬組成物
US20040115739A1 (en) *	2002-01-25	2004-06-17	Garcia Maria L	Method for identifying maxi-k channel blockers for use in lowering elevated intraocular pressure using hek-293 cells
US7119112B2 (en) *	2002-02-28	2006-10-10	Icagen, Inc.	Sulfonamides as potassium channel blockers
JP2005526052A (ja) *	2002-02-28	2005-09-02	アイカゲンインコーポレイテッド	眼内圧に関連する疾患を処置するための方法
WO2003077845A2 (en) *	2002-03-15	2003-09-25	Merck & Co., Inc.	Compositions and methods for treating glaucoma and ocular hypertension
CA2488802A1 (en) *	2002-06-14	2003-12-24	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
EP1515974A4 (de) *	2002-06-17	2007-02-28	Merck & Co Inc	Neue maxi-k-kanalblocker, anwendungsverfahren und verfahren zu dessen herstellung
EP1515730A4 (de) *	2002-06-17	2005-07-20	Merck & Co Inc	Neue maxi-k-kanalblocker, verwendungsmethode und verfahren zu ihrer herstellung
US7196082B2 (en)	2002-11-08	2007-03-27	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
EP1581503A4 (de) *	2002-11-08	2007-07-25	Merck & Co Inc	Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
JP2006524239A (ja)	2003-03-27	2006-10-26	メルク　エンド　カムパニー　インコーポレーテッド	高眼圧症を治療するための眼用組成物
AU2004253543B2 (en) *	2003-07-01	2009-02-19	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
JP2007504228A (ja) *	2003-09-02	2007-03-01	メルク　エンド　カムパニー　インコーポレーテッド	高眼圧症を治療するための眼組成物
US7494983B2 (en) *	2003-09-04	2009-02-24	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
KR20060090801A (ko) *	2003-09-04	2006-08-16	머크 앤드 캄파니 인코포레이티드	고안압증 치료용 안용 조성물
US20050250779A1 (en) *	2004-05-04	2005-11-10	Song Zhu	Pteridinone derivatives for treating ocular hypertension
AU2005274972A1 (en)	2004-07-20	2006-02-23	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
CA2583593A1 (en) *	2004-10-13	2006-04-27	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
AU2005295831A1 (en) *	2004-10-13	2006-04-27	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
EP2004193A2 (de) *	2006-03-13	2008-12-24	Merck & Co., Inc.	Ophthalmische zusammensetzungen zur behandlung von augenhochdruck
AU2007258527A1 (en) *	2006-06-12	2007-12-21	Merck Sharp & Dohme Corp.	Ophthalmic compositions for treating ocular hypertension
EP1941876A1 (de) *	2006-12-28	2008-07-09	Lacer, S.A.	Isosorbidmononitrit Derivate zur Behandlung von der Inflammation und okularen Hypertension
EP2436387B1 (de) *	2009-05-25	2018-07-25	Celgene Corporation	Pharmazeutische zusammensetzung enthaltend crbn zur verwendung in der behandlung von krankeiten des cerebralen cortex.
CA2834535A1 (en)	2011-04-29	2012-11-01	Celgene Corporation	Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP3904875B1 (de)	2012-06-29	2024-11-20	Celgene Corporation	Verfahren zur bestimmung der wirksamkeit von arzneimitteln anhand von ikzf3 (aiolos)
US9587281B2 (en)	2012-08-14	2017-03-07	Celgene Corporation	Cereblon isoforms and their use as biomarkers for therapeutic treatment
ES2843973T3 (es)	2014-06-27	2021-07-21	Celgene Corp	Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
WO2017117118A1 (en)	2015-12-28	2017-07-06	Celgene Corporation	Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3693789A (en) *	1988-05-10	1989-11-29	Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab)	New ophthalmic preparation for treating glaucoma
EP0430621A3 (en) *	1989-11-29	1992-03-04	Beecham Group P.L.C.	Process for the preparation of chiral 3,4-epoxy benzopyrans
US5512591A (en) *	1993-02-18	1996-04-30	President And Fellows Of Harvard College	Treatments for diseases characterized by neovascularization
EP0724443A4 (de) *	1993-06-08	1997-09-10	Vide Pharmaceuticals	Verfahren und präparate zur senkung des augeninnendrucks
US5494895A (en) *	1993-07-22	1996-02-27	Merck & Co., Inc.	Scorpion peptide margatoxin with immunosuppressant activity
GB9316111D0 (en) *	1993-08-04	1993-09-22	Pfizer Ltd	Benzopyrans

1995
- 1995-04-28 US US08/431,170 patent/US5573758A/en not_active Expired - Lifetime
1996
- 1996-04-16 DE DE69630325T patent/DE69630325T3/de not_active Expired - Lifetime
- 1996-04-16 AT AT96912798T patent/ATE225658T1/de not_active IP Right Cessation
- 1996-04-16 WO PCT/US1996/005241 patent/WO1996033719A1/en not_active Ceased
- 1996-04-16 AU AU55488/96A patent/AU703241B2/en not_active Ceased
- 1996-04-16 JP JP8532585A patent/JPH11504330A/ja not_active Withdrawn
- 1996-04-16 EP EP02009867A patent/EP1243270B2/de not_active Expired - Lifetime
- 1996-04-16 ES ES02009867T patent/ES2204879T5/es not_active Expired - Lifetime
- 1996-04-16 AT AT02009867T patent/ATE251458T1/de not_active IP Right Cessation
- 1996-04-16 EP EP96912798A patent/EP0825863B1/de not_active Expired - Lifetime
- 1996-04-16 ES ES96912798T patent/ES2182973T3/es not_active Expired - Lifetime
- 1996-04-16 DE DE69624234T patent/DE69624234D1/de not_active Expired - Lifetime
2007
- 2007-06-06 JP JP2007150243A patent/JP2007217437A/ja active Pending

Also Published As

Publication number	Publication date
ES2204879T3 (es)	2004-05-01
AU5548896A (en)	1996-11-18
DE69624234D1 (de)	2002-11-14
EP1243270A1 (de)	2002-09-25
US5573758A (en)	1996-11-12
ATE225658T1 (de)	2002-10-15
DE69630325T3 (de)	2009-11-19
JP2007217437A (ja)	2007-08-30
JPH11504330A (ja)	1999-04-20
WO1996033719A1 (en)	1996-10-31
ES2182973T3 (es)	2003-03-16
AU703241B2 (en)	1999-03-25
DE69630325T2 (de)	2004-07-29
EP1243270B1 (de)	2003-10-08
ATE251458T1 (de)	2003-10-15
ES2204879T5 (es)	2009-06-19
EP0825863B1 (de)	2002-10-09
EP1243270B2 (de)	2009-03-25
EP0825863A1 (de)	1998-03-04

Publication	Publication Date	Title
DE69630325D1 (de)	2003-11-13	Nervenschutzende für Auge von Säugern unter Anwendung von Kaliumkanalblockern
BR9611748A (pt)	1999-06-01	Uso de um produto protéico de fator neurotrófico derivado de linhagem de célula glial
ES2062102T3 (es)	1994-12-16	Derivados de prostaglandinas para el tratamiento de glaucoma o hipertension ocular.
ATE480240T1 (de)	2010-09-15	Zusammensetzung enthaltend latanoprost und behandlungsmethode von erhöhtem augeninnendruck und glaukom
EP1110554A4 (de)	2002-02-06	Medizinische zusammensetzungen zur behandlung von augenerkrankungen
BR0210241A (pt)	2004-08-10	Piranoindazóis e seu uso no tratamento de glaucoma
ATE162074T1 (de)	1998-01-15	Oculare hypotensive mittel
DE69320405D1 (de)	1998-09-24	Ophthalmische Zusammensetzungen enthaltend als Wirkstoff Vitamin-E oder Ester davon
BR9914128A (pt)	2002-09-24	Composições antibióticas para tratamento do olho, ouvido e nariz
DE69626232D1 (de)	2003-03-27	Behandlung von N. opticus-Beschwerden mit einem Prostansäurederivat
BR0210238A (pt)	2004-07-20	Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
ATE233554T1 (de)	2003-03-15	Produkte zur behandlung von glaukoma
BR9302024A (pt)	1993-11-30	Composicao cosmetica apropriada para aplicacao topica na pele ou cabelo de mamiferos e processos para a producao da mesma e para tratamento cosmetico
ATE359774T1 (de)	2007-05-15	Taurinderivate verwendbar in der behandlung von netzhauterkrankungen
DE69011054D1 (de)	1994-09-01	Substituierte cyclohexene mit zentraler Nervensystem-Wirkung.
BR0113201A (pt)	2006-05-09	processo para tratar distúrbios neurodegenerativos da retina e da cabeça do nervo óptico
EP1410808A4 (de)	2009-07-29	Mittel zum schutz des sehnervs mit alpha-1-rezeptor-blocker als wirkstoff
BR9915803A (pt)	2001-08-21	Composição para o tratamento de neuropatia da retina ou cabeça de nervo ótico, e, processo para tratamento de neuropatia da retina ou cabeça de nervo ótico
CA2219280A1 (en)	1996-10-31	Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
DE69829227D1 (de)	2005-04-07	Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
PT1051973E (pt)	2004-11-30	Agentes de melhoramento da circulacao optica papilar
EP1325744A4 (de)	2005-08-17	Mittel zur behandlungen von retinalen nervenerkrankungen mit 1,2-ethandiolderivaten oder salzen davon

Legal Events

Date	Code	Title	Description
2004-01-15	8327	Change in the person/name/address of the patent owner	Owner name: ALLERGAN, INC., IRVINE, CALIF., US
2004-10-07	8363	Opposition against the patent
2009-06-04	8366	Restricted maintained after opposition proceedings
2009-08-27	8328	Change in the person/name/address of the agent	Representative=s name: DR. SWEN HENTRICH UND DR. CHRISTIAN KRAUNS, 89073